Scarica l'app Stockscreener
76.62
5.16%
3.76
Dopo l'orario di chiusura:
76.45
-0.17
-0.22%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$72.86
Aprire:
$73.908
Volume 24 ore:
7.45M
Relative Volume:
1.41
Capitalizzazione di mercato:
$29.57B
Reddito:
$4.82B
Utile/perdita netta:
$930.40M
Rapporto P/E:
32.77
EPS:
2.3381
Flusso di cassa netto:
$1.43B
1 W Prestazione:
+2.34%
1M Prestazione:
+26.41%
6M Prestazione:
+16.76%
1 anno Prestazione:
-11.60%
Intervallo 1D:
$73.00
$78.52
Intervallo di 1 settimana:
$71.53
$78.52
Portata 52W:
$54.11
$89.98
Dexcom Inc Stock (DXCM) Company Profile
Nome
Dexcom Inc
Settore
Industria
Telefono
(858) 200-0200
Indirizzo
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
76.62 | 28.11B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
90.50 | 158.63B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
301.53 | 117.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
80.69 | 104.85B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
48.70 | 72.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.85 | 49.50B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-24 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2026-01-12 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Iniziato | Evercore ISI | In-line |
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Iniziato | Argus | Buy |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-03 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Iniziato | Redburn Atlantic | Neutral |
| 2024-03-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2023-01-26 | Iniziato | Wolfe Research | Outperform |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-15 | Iniziato | Bernstein | Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-28 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2021-01-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-02 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Reiterato | Piper Sandler | Overweight |
| 2020-05-14 | Iniziato | Wells Fargo | Equal Weight |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-11-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-10-23 | Iniziato | Stifel | Buy |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-09-12 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Reiterato | Canaccord Genuity | Buy |
| 2018-07-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
| 2018-05-03 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-04 | Iniziato | Goldman | Sell |
| 2018-04-04 | Iniziato | Guggenheim | Neutral |
| 2018-03-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Reiterato | Wedbush | Outperform |
Mostra tutto
Dexcom Inc Borsa (DXCM) Ultime notizie
DexCom Inc. stock outperforms competitors on strong trading day - MSN
Clinical Wins Boost Dexcom Growth Story In Type 2 Diabetes - Benzinga
DexCom Reports Positive CONNECT Data for Non-Insulin Diabetes - Yahoo Finance Singapore
DexCom jumps as new ADA trial data boosts optimism for broader CGM adoption - Quiver Quantitative
Why is DexCom stock surging today? By Investing.com - Investing.com Canada
Mizuho Securities Adjusts DexCom Price Target to $85 From $75, Maintains Outperform Rating - marketscreener.com
Here's why you should retain DexCom stock in your portfolio - MSN
DexCom (DXCM) Reports Positive Trial Results for Glucose Control in Type 2 Diabetes - GuruFocus
Is DexCom stock underperforming the Dow? - MSN
Is It Time To Reassess DexCom (DXCM) After Recent Glucose Monitoring Headlines? - Sahm
Dexcom G7 gave Type 2 adults 5 extra hours a day in range - Stock Titan
Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in study - Reuters
DexCom, Inc. Announces Results From CONNECT Randomized Controlled Trial Demonstrating Use Of Dexcom G7 Leads To Clinically And Statistically Significant Reduction In A1C And Improvement In Glucose Control Among People With Type 2 Diabetes N - marketscreener.com
Assessing DexCom (DXCM) Valuation After Recent Share Price Momentum - Yahoo Finance
Dexcom buys Nutrisense; Insulet rolls out patch pump update - MedTech Dive
Stifel Adjusts Price Target on DexCom to $90 From $85, Maintains Buy Rating - marketscreener.com
Is DexCom Stock Underperforming the Dow? - Yahoo Finance
DXCM to launch Dexcom Flex CGM system for type 2 diabetes in Germany - MSN
Here's Why You Should Retain DexCom Stock in Your Portfolio - The Globe and Mail
[Latest] Non-Invasive Blood Glucose Monitoring Devices Market Size to Hit USD 340.49 Million with a Promising CAGR of 25.60% by 2034 - GlobeNewswire Inc.
DexCom (DXCM) Showcases Innovations and Future Plans at ADA Scie - GuruFocus
DexCom vs. Insulet: Growth Trajectories and Valuations for InvestorsNews and Statistics - IndexBox
DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026? - Yahoo Finance
Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026 - 01net
Dexcom Reaffirms CGM Benefits for All People With Diabetes and C - GuruFocus
Dexcom to present diabetes study, launch new app, acquire Nutrisense - Investing.com
Elliott strikes Dexcom board settlement after taking stake - MSN
Did FDA-App Recalls and Activist Pressure Just Rewire Dexcom’s (DXCM) Software-Driven Investment Narrative? - Yahoo Finance
Dexcom Inc. stock (US2521311074): customer advisory report and recent trading in focus - AD HOC NEWS
DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
The FDA Has Issued a Warning on 2 Popular Glucose Monitors. You Won't Believe Why. - Men's Health
Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience - 01net
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $85 - Moomoo
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DexCom - TMX Newsfile
Research Alert: CFRA Maintains Hold Rating On Shares Of Dexcom Inc. - Moomoo
DexCom (NASDAQ: DXCM) director receives 5,605 RSUs equity grant - Stock Titan
DexCom Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Here's why you should hold DexCom stock in your portfolio for now - MSN
Dexcom Inc. stock (US2521311074): shares trade mixed as investors look beyond latest earnings and gu - AD HOC NEWS
DexCom, Inc. (DXCM) Investor Outlook: A Healthcare Stock With 12.28% Upside Potential - DirectorsTalk Interviews
DXCM Stock Price, Quote & Chart | DEXCOM INC (NASDAQ:DXCM) - ChartMill
Dexcom Inc. stock (US2521311074): institutional buying and technical picture on Nasdaq - AD HOC NEWS
Stolen medical devices that failed quality control were sold to the public - Yahoo
Elliott to get two board seats at Dexcom ahead of investor day - MSN
DexCom Inc. stock underperforms Friday when compared to competitors - MSN
How Investors May Respond To DexCom (DXCM) Global App Recalls Over Delayed Glucose Alerts - Sahm
Dexcom Inc. stock (US2521311074): shares edge lower after recent Nasdaq volatility - AD HOC NEWS
Dexcom, Inc. 8-K Filing Summary: Company Details, Stock Info, and Regulatory Compliance (May 27, 2026) - Minichart
DexCom, Inc. (DXCM) Announces Results of 2026 Annual Meeting of Stockholders - GuruFocus
Dexcom Inc Azioni (DXCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Dexcom Inc Azioni (DXCM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Coleman Jon | EVP, Chief Commercial Officer |
Jun 03 '26 |
Sale |
73.00 |
4,912 |
358,576 |
100,361 |
0.00%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):